”la Caixa” Foundation, within the CaixaImpulse Health Innovation Call 2023, has awarded a total of €3.3 millions to 29 health innovation projects. Two of these projects are led by researchers at Vall d'Hebron Research Institute (VHIR).

CaixaImpulse Innovation helps to transfer scientific knowledge to society and encourages the creation of new products, services and companies related to life sciences. It supports innovative biomedical projects by helping them to validate their asset/s and define their valorisation and exploitation strategy, and by bringing them closer to the market.

The call is carried out in collaboration with Caixa Capital Risc, one of the leading venture capital investors in Spain, with more than twenty years of experience.

Below is a list of VHIR projects that have been selected for this programme:

New predictive biomarker for the development and progression of non-alcoholic fatty liver disease

• Leader of the project: David Martínez Selva, principal investigator of the Diabetes and Metabolism group at VHIR
• Grant received: 50.000 euros

Non-alcoholic fatty liver disease is one of the most common liver diseases in the world. It is caused by excessive fat accumulation in the liver and is exacerbated by factors like obesity and diabetes. It is known as the "silent killer disease" because its progression is very gradual and most patients with the disease do not experience symptoms and therefore remain unaware of their condition. Around 25 % of patients develop non-alcoholic steatohepatitis, characterised by liver inflammation and fibrosis, which can lead to pathologies such as liver cirrhosis or cancer. It is estimated that by 2023 this disease will become the main reason for liver transplantation globally.

There are still no approved drugs available to treat non-alcoholic fatty liver disease. One of the main reasons for this is the lack of non-invasive clinical biomarkers, which poses a significant challenge for the development of new medications. While certain molecules have been identified as potential biomarkers, biopsy remains one of the most routine diagnostic techniques. Its main disadvantages include its invasive nature and the variability of the technique. This highlights the urgent need for non-invasive biomarkers that facilitate both the diagnosis and monitoring of disease progression and the therapeutic efficacy of treatments under development.

In previous studies with an animal model, the team has identified two proteins which, when combined with a mathematical algorithm, can be used as a non-invasive biomarker to predict the onset and progression of various stages of the disease, including the most severe ones, such as steatohepatitis. The project aims to advance in the validation of this new biomarker, which could offer an alternative to liver biopsy. It will help identify individuals suffering from the disease and predict its progression, which will have important implications for improving their quality of life. It will also facilitate the development of new drugs to treat these conditions.

A new immunosuppressive drug to prevent organ transplant rejection

• Leader of the project: Oriol Bestard, head of the Nephrology Department at Vall d'Hebron University Hospital and co-head of the Nephrology and kidney transplantation group at VHIR
• Grant received: 148.500 euros

Organ, tissue and cell transplantation has become a global practice that can prolong and improve the quality of life for patients. Advances in harvesting, preservation, transplantation and immunosuppression techniques have improved the effectiveness of transplants. However, although the volume of organ transplants has grown exponentially over recent years, long-term transplant outcomes have not improved much in the last few decades. This is primarily due to the significant side effects of current immunosuppressive drugs, which are essential to prevent immediate transplant rejection but result in high associated morbidity and mortality.

The project team has developed a second-generation immunosuppressive molecule, structurally modified to enhance its immunomodulatory properties and effectively prevent transplant rejection by suppressing the activity of T and B cells, which are the main immune system cells responsible for causing transplant rejection. This molecule inhibits the production of antibodies against the transplanted organ by B lymphocytes, thereby improving the immunosuppressive profile of the immunosuppressants currently in use, but with the important difference that it lacks the most relevant adverse effects associated with these drugs.

In this phase, the objectives of the project are to compare the in vivo efficacy of this new immunosuppressive drug with respect to commonly used treatments in two experimental animal models, evaluate the mechanisms that prevent transplant rejection through the new molecule, conduct performance studies including the development of a stable production line for the drug and establish a pre-clinical regulatory strategy for technology transfer.